DNA damage repair genes alterations in pancreatic neuroendocrine tumor treated with Temozolomide

#4182

Introduction: Temozolomide (TMZ), a standard therapy for pancreatic neuroendocrine tumors (pNETs), is an alkylating agent causing missense mutations and triggering cell death.

Aim(s): We assayed DNA Damage Repair (DDR) genes alteration occurrence in a cohort of TMZ-treated pNETs analyzed by NGS at our Institution.

Materials and methods: We retrospectively collected our cohort. NGS samples were analyzed from tissue (174-genes panel) or liquid biopsy (FoundationOne). Only ACMG/AMP class IV-V molecular alterations were considered. Clonality threshold for Variant Allele Frequency of mutations was >10%. TMB high threshold was >15 mut/mb.

Conference:

Presenting Author: Trevisani E

Authors: Trevisani E, Reni A, Torresan I, Borghesani M, Rossi A,

Keywords: DNA Damage Repair, Tumor mutational burden, Neuroendocrine, Temozolomide,